Lonza has been looking for a way to more efficiently fill-and-finish its injectable drugs and has found a solution by buying a Novartis bottling plant.
The company said it was debating whether it should build a new facility or purchase one and opted to buy a 10-year-old Novartis plant in Stein, Switzerland. Lonza said the purchase will allow the company to speed its operations as it works to more quickly get its injectable drugs onto the market.
Lonza plans to retain all of the facility’s current employees and utilize their expertise. Lonza will also continue making products for Novartis at the site.
Read the full Reuters report.